相关临床试验
2
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
50.0%
招募中
1
50.0%
暂无批准数据
- Serina Therapeutics received FDA clearance for its Investigational New Drug application for SER-252, an investigational therapy targeting advanced Parkinson's disease. - The IND clearance enables the company to proceed with regulatory and site-level preparations for a planned Phase 1b registrational clinical trial. - The FDA has aligned on a 505(b)(2) New Drug Application pathway for the program, which allows approval for drugs that partly rely on published literature or FDA findings. - SER-252 utilizes Serina's proprietary POZ Platform technology, a poly(2-oxazoline)-based polymer system designed for controlled drug release via subcutaneous injection.
- Serina Therapeutics submitted a complete response to the FDA's clinical hold letter for SER-252, addressing concerns about the formulation excipient trehalose. - The FDA clinical hold does not relate to the apomorphine active drug substance or its mechanism of action, maintaining the 505(b)(2) development pathway. - The company targets first-patient-in for the Phase 1b registrational study in Q1 2026, subject to FDA feedback and clinical hold resolution. - SER-252 is designed to provide continuous dopaminergic stimulation for advanced Parkinson's disease using Serina's proprietary POZ platform technology.
- Serina Therapeutics announced the advancement of SER-270 (POZ-VMAT2i), a novel once-weekly subcutaneous VMAT2 inhibitor designed to address medication adherence challenges in tardive dyskinesia patients. - The drug candidate targets underserved patient populations including those non-compliant with daily oral medications, institutionalized patients, and individuals with swallowing difficulties. - The U.S. tardive dyskinesia market exceeded $3.7 billion in 2024 and is projected to reach $5.4 billion by 2030, despite fewer than 30% of patients being diagnosed. - Serina plans to explore POZ-VMAT2i development for Huntington's disease chorea as a secondary indication, leveraging advantages for patients with swallowing difficulties.
- Serina Therapeutics, known for its polymer drug delivery platform targeting CNS disorders, has filed a $100 million mixed securities shelf offering to strengthen its financial position for ongoing R&D initiatives. - enVVeno Medical, focused on developing innovative treatments for venous diseases including the VenoValve, has similarly filed a $100 million mixed securities shelf to support its clinical development pipeline. - These parallel financial moves reflect a strategic trend among specialized biotech companies to secure flexible funding options amid challenging market conditions for pharmaceutical development.
- Huntsville-based Serina Therapeutics has secured $10 million funding from UK's JuvVentures to advance their innovative drug delivery system for Parkinson's disease treatment. - The biotechnology company is developing an enhanced delivery method for apomorphine, combining their proprietary technology with Enable Injections' wearable device for improved patient administration. - Clinical trials are scheduled to commence in the second half of 2025, aiming to provide longer-lasting therapeutic effects for advanced Parkinson's disease patients.
- Serina Therapeutics' SER-252, a novel apomorphine therapy, is set to begin Phase 1 clinical trials in the second half of 2025 for advanced Parkinson's disease. - SER-252 utilizes Serina's POZ Platform for continuous dopaminergic stimulation, aiming to reduce motor complications and improve 'on time' for patients. - Serina Therapeutics secured a $5 million tranche of equity financing, strengthening its financial position to advance SER-252 into human studies. - The POZ Platform enhances drug delivery through controlled release and safe metabolism, potentially offering significant benefits for Parkinson's patients.
- Serina Therapeutics secured $10 million in equity financing from JuvVentures to advance SER-252 for advanced Parkinson's disease. - The financing involves issuing shares at $10 each, a 120% premium over the November 26 closing price, signaling strong investor confidence. - SER-252, a POZ-apomorphine formulation, aims to provide continuous dopaminergic stimulation, potentially reducing motor complications in Parkinson's patients. - Phase 1 clinical trials for SER-252 are scheduled to begin in the second half of 2025, marking a critical milestone for the drug's development.
